Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 375

1.

Efficacy and safety of dapagliflozin in Japanese patients with inadequately controlled type 1 diabetes (DEPICT-5): 52-week results from a randomized, open-label, phase III clinical trial.

Araki E, Watada H, Uchigata Y, Tomonaga O, Fujii H, Ohashi H, Okabe T, Asano M, Thoren F, Kim H, Yajima T, Langkilde AM.

Diabetes Obes Metab. 2019 Nov 19. doi: 10.1111/dom.13922. [Epub ahead of print]

PMID:
31742898
2.

Clinical Features of Patients with Acute Aortic Dissection After an Earthquake ~Experience from The Kumamoto Earthquake 2016~.

Komorita T, Fujisue K, Sueta D, Sakamoto K, Yamamoto E, Hashimoto Y, Sakamoto T, Tsunoda R, Uesugi H, Suzuki R, Naito H, Hanzawa K, Araki E, Nakayama H, Kasaoka S, Hokimoto S, Fukui T, Tsujita K.

Am J Hypertens. 2019 Nov 18. pii: hpz183. doi: 10.1093/ajh/hpz183. [Epub ahead of print]

PMID:
31738384
3.

Efficacy and Safety of Pemafibrate, a Novel Selective Peroxisome Proliferator-Activated Receptor α Modulator (SPPARMα): Pooled Analysis of Phase 2 and 3 Studies in Dyslipidemic Patients with or without Statin Combination.

Yamashita S, Arai H, Yokote K, Araki E, Matsushita M, Nojima T, Suganami H, Ishibashi S.

Int J Mol Sci. 2019 Nov 6;20(22). pii: E5537. doi: 10.3390/ijms20225537.

4.

Differential predictive factors for cardiovascular events in patients with or without cancer history.

Sueta D, Tabata N, Ikeda S, Saito Y, Ozaki K, Sakata K, Matsumura T, Yamamoto-Ibusuki M, Murakami Y, Jodai T, Fukushima S, Yoshida N, Kamba T, Araki E, Iwase H, Fujii K, Ihn H, Kobayashi Y, Minamino T, Yamagishi M, Maemura K, Baba H, Matsui K, Tsujita K.

Medicine (Baltimore). 2019 Nov;98(44):e17602. doi: 10.1097/MD.0000000000017602.

5.

Efficacy, Safety, and Tolerability of Oral Semaglutide Versus Placebo Added to Insulin With or Without Metformin in Patients With Type 2 Diabetes: The PIONEER 8 Trial.

Zinman B, Aroda VR, Buse JB, Cariou B, Harris SB, Hoff ST, Pedersen KB, Tarp-Johansen MJ, Araki E; PIONEER 8 Investigators.

Diabetes Care. 2019 Dec;42(12):2262-2271. doi: 10.2337/dc19-0898. Epub 2019 Sep 17.

PMID:
31530667
6.

Long-Term Efficacy and Safety of Linagliptin in a Japanese Population with Type 2 Diabetes Aged ≥ 60 Years Treated with Basal Insulin: A Randomised Trial.

Araki E, Unno Y, Tanaka Y, Sakamoto W, Miyamoto Y.

Adv Ther. 2019 Oct;36(10):2697-2711. doi: 10.1007/s12325-019-01065-7. Epub 2019 Sep 3.

7.

Superior efficacy with a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with insulin degludec and liraglutide in insulin-naïve Japanese patients with type 2 diabetes in a phase 3, open-label, randomized trial.

Kaku K, Araki E, Tanizawa Y, Ross Agner B, Nishida T, Ranthe M, Inagaki N.

Diabetes Obes Metab. 2019 Dec;21(12):2674-2683. doi: 10.1111/dom.13856. Epub 2019 Aug 28.

PMID:
31407845
8.

Comparison of the efficacy and safety of once-daily insulin degludec/insulin aspart (IDegAsp) and long-acting second-generation basal insulin (insulin degludec and insulin glargine 300 units/mL) in insulin-naïve Japanese adults with type 2 diabetes: a pilot, randomized, controlled study.

Shimoda S, Sakamoto W, Hokamura A, Matsuo Y, Sekigami T, Ichimori S, Iwashita S, Ishii N, Otsu K, Yoshimura R, Nishiyama T, Sakaguchi M, Nishida K, Araki E.

Endocr J. 2019 Aug 29;66(8):745-752. doi: 10.1507/endocrj.EJ19-0179. Epub 2019 Jul 12.

9.

Effectiveness of inactivated influenza vaccine in children by vaccine dose, 2013-18.

Shinjoh M, Sugaya N, Furuichi M, Araki E, Maeda N, Isshiki K, Ohnishi T, Nakamura S, Yamada G, Narabayashi A, Nishida M, Taguchi N, Nakata Y, Yoshida M, Tsunematsu K, Shibata M, Munenaga T, Hirano Y, Ookawara I, Sekiguchi S, Kobayashi Y, Yamaguchi Y, Yoshida N, Mitamura K, Takahashi T; Keio Pediatric Influenza Research Group.

Vaccine. 2019 Jul 9;37(30):4047-4054. doi: 10.1016/j.vaccine.2019.05.090. Epub 2019 Jun 8.

PMID:
31186191
10.

Short-Term Cost-Effectiveness of Switching to Insulin Degludec in Japanese Patients with Type 2 Diabetes Receiving Basal-Bolus Therapy.

Langer J, Wolden ML, Shimoda S, Sato M, Araki E.

Diabetes Ther. 2019 Aug;10(4):1347-1356. doi: 10.1007/s13300-019-0635-1. Epub 2019 Jun 5.

11.

Pioglitazone suppresses macrophage proliferation in apolipoprotein-E deficient mice by activating PPARγ.

Murakami-Nishida S, Matsumura T, Senokuchi T, Ishii N, Kinoshita H, Yamada S, Morita Y, Nishida S, Motoshima H, Kondo T, Komohara Y, Araki E.

Atherosclerosis. 2019 Jul;286:30-39. doi: 10.1016/j.atherosclerosis.2019.04.229. Epub 2019 May 3.

PMID:
31096071
12.

Mineralocorticoid Receptor May Regulate Glucose Homeostasis through the Induction of Interleukin-6 and Glucagon-Like peptide-1 in Pancreatic Islets.

Goto R, Kondo T, Ono K, Kitano S, Miyakawa N, Watanabe T, Sakaguchi M, Sato M, Igata M, Kawashima J, Motoshima H, Matsumura T, Shimoda S, Araki E.

J Clin Med. 2019 May 14;8(5). pii: E674. doi: 10.3390/jcm8050674.

13.

FoxK1 and FoxK2 in insulin regulation of cellular and mitochondrial metabolism.

Sakaguchi M, Cai W, Wang CH, Cederquist CT, Damasio M, Homan EP, Batista T, Ramirez AK, Gupta MK, Steger M, Wewer Albrechtsen NJ, Singh SK, Araki E, Mann M, Enerbäck S, Kahn CR.

Nat Commun. 2019 Apr 5;10(1):1582. doi: 10.1038/s41467-019-09418-0.

14.

Efficacy and safety of pemafibrate in people with type 2 diabetes and elevated triglyceride levels: 52-week data from the PROVIDE study.

Araki E, Yamashita S, Arai H, Yokote K, Satoh J, Inoguchi T, Nakamura J, Maegawa H, Yoshioka N, Tanizawa Y, Watada H, Suganami H, Ishibashi S.

Diabetes Obes Metab. 2019 Jul;21(7):1737-1744. doi: 10.1111/dom.13686. Epub 2019 Apr 1.

15.

Correction to: Japanese Clinical Practice Guideline for Diabetes 2016.

Haneda M, Noda M, Origasa H, Noto H, Yabe D, Fujita Y, Goto A, Kondo T, Araki E.

Diabetol Int. 2018 Dec 4;10(1):83. doi: 10.1007/s13340-018-0385-8. eCollection 2019 Jan.

16.
17.

Long-Term Efficacy and Safety of Pemafibrate, a Novel Selective Peroxisome Proliferator-Activated Receptor-α Modulator (SPPARMα), in Dyslipidemic Patients with Renal Impairment.

Yokote K, Yamashita S, Arai H, Araki E, Suganami H, Ishibashi S, Of The K-Study Group OB.

Int J Mol Sci. 2019 Feb 6;20(3). pii: E706. doi: 10.3390/ijms20030706.

18.

Hyperemesis gravidarum followed by refeeding syndrome causes electrolyte abnormalities induced rhabdomyolysis and diabetes insipidus.

Kondo T, Nakamura M, Kawashima J, Matsumura T, Ohba T, Yamaguchi M, Katabuchi H, Araki E.

Endocr J. 2019 Mar 28;66(3):253-258. doi: 10.1507/endocrj.EJ18-0496. Epub 2019 Jan 29.

19.

Japanese Clinical Practice Guideline for Diabetes 2016.

Haneda M, Noda M, Origasa H, Noto H, Yabe D, Fujita Y, Goto A, Kondo T, Araki E.

Diabetol Int. 2018 Mar 27;9(1):1-45. doi: 10.1007/s13340-018-0345-3. eCollection 2018 Feb. Review. No abstract available. Erratum in: Diabetol Int. 2018 Dec 4;10(1):83.

20.

Impact of hepatic HSP72 on insulin signaling.

Kitano S, Kondo T, Matsuyama R, Ono K, Goto R, Takaki Y, Hanatani S, Sakaguchi M, Igata M, Kawashima J, Motoshima H, Matsumura T, Kai H, Araki E.

Am J Physiol Endocrinol Metab. 2019 Feb 1;316(2):E305-E318. doi: 10.1152/ajpendo.00215.2018. Epub 2018 Dec 11.

PMID:
30532989
21.

Pharmacokinetics and pharmacodynamics of dapagliflozin in combination with insulin in Japanese patients with type 1 diabetes.

Watada H, Shiramoto M, Ueda S, Tang W, Asano M, Thorén F, Kim H, Yajima T, Boulton DW, Araki E.

Diabetes Obes Metab. 2018 Nov 30. doi: 10.1111/dom.13593. [Epub ahead of print]

22.

Experimental evidence characterizing pressure fluctuations at the seafloor-water interface induced by an earthquake.

Matsumoto H, Kimura T, Nishida S, Machida Y, Araki E.

Sci Rep. 2018 Nov 6;8(1):16406. doi: 10.1038/s41598-018-34578-2.

23.

Study Design of a Phase II Clinical Trial to Assess the Efficacy and Safety of Eperisone in Japanese Type 2 Diabetes Patients with Risk and Non-risk Alleles of CDKAL1.

Sakakida K, Wei FY, Senokuchi T, Shimoda S, Kakuma T, Araki E, Tomizawa K; Eperisone for Diabetes with Impaired tRNA (EDIT) Study Group.

Acta Med Okayama. 2018 Aug;72(4):423-426. doi: 10.18926/AMO/56182.

24.

A Rare Case of Thyrotropin-Secreting Pituitary Adenoma Coexisting with Papillary Thyroid Carcinoma Presenting with Visual Disturbance without Hyperthyroidism.

Inoue H, Shinojima N, Ueda R, Yamamoto K, Ishii N, Igata M, Kawashima J, Araki E, Iwase H, Mikami Y, Yano S, Mukasa A.

World Neurosurg. 2018 Nov;119:394-399. doi: 10.1016/j.wneu.2018.07.274. Epub 2018 Aug 7.

PMID:
30096503
25.

Effects of pemafibrate (K-877) on cholesterol efflux capacity and postprandial hyperlipidemia in patients with atherogenic dyslipidemia.

Yamashita S, Arai H, Yokote K, Araki E, Suganami H, Ishibashi S; K-877 Study Group.

J Clin Lipidol. 2018 Sep - Oct;12(5):1267-1279.e4. doi: 10.1016/j.jacl.2018.06.010. Epub 2018 Jun 26.

26.

Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes (the DEPICT-2 Study): 24-Week Results From a Randomized Controlled Trial.

Mathieu C, Dandona P, Gillard P, Senior P, Hasslacher C, Araki E, Lind M, Bain SC, Jabbour S, Arya N, Hansen L, Thorén F, Langkilde AM; DEPICT-2 Investigators.

Diabetes Care. 2018 Sep;41(9):1938-1946. doi: 10.2337/dc18-0623. Epub 2018 Jul 19.

PMID:
30026335
27.

Impacts of the 2016 Kumamoto Earthquake on glycemic control in patients with diabetes.

Kondo T, Miyakawa N, Motoshima H, Hanatani S, Ishii N, Igata M, Yoshinaga K, Kukidome D, Senokuchi T, Kawashima J, Furukawa N, Matsumura T, Araki E.

J Diabetes Investig. 2019 Mar;10(2):521-530. doi: 10.1111/jdi.12891. Epub 2018 Aug 1.

28.

Impacts of tight multifactorial intervention in patients with type 2 diabetes: Implications from the Japan Diabetes Outcome Intervention Trial 3.

Araki E, Senokuchi T, Furukawa N.

J Diabetes Investig. 2018 Sep;9(5):1022-1024. doi: 10.1111/jdi.12872. Epub 2018 Jul 18. Review.

29.

Production of high oleic/low linoleic rice by genome editing.

Abe K, Araki E, Suzuki Y, Toki S, Saika H.

Plant Physiol Biochem. 2018 Oct;131:58-62. doi: 10.1016/j.plaphy.2018.04.033. Epub 2018 Apr 26.

PMID:
29735369
30.

Semaglutide Added to Basal Insulin in Type 2 Diabetes (SUSTAIN 5): A Randomized, Controlled Trial.

Rodbard HW, Lingvay I, Reed J, de la Rosa R, Rose L, Sugimoto D, Araki E, Chu PL, Wijayasinghe N, Norwood P.

J Clin Endocrinol Metab. 2018 Jun 1;103(6):2291-2301. doi: 10.1210/jc.2018-00070.

31.

Efficacy and Safety of Pemafibrate Versus Fenofibrate in Patients with High Triglyceride and Low HDL Cholesterol Levels: A Multicenter, Placebo-Controlled, Double-Blind, Randomized Trial.

Arai H, Yamashita S, Yokote K, Araki E, Suganami H, Ishibashi S; K-877 Study Group.

J Atheroscler Thromb. 2018 Jun 1;25(6):521-538. doi: 10.5551/jat.44412. Epub 2018 Apr 7.

32.

One-hour oral glucose tolerance test plasma glucose at gestational diabetes diagnosis is a common predictor of the need for insulin therapy in pregnancy and postpartum impaired glucose tolerance.

Nishikawa T, Ono K, Hashimoto S, Kinoshita H, Watanabe T, Araki H, Otsu K, Sakamoto W, Harada M, Toyonaga T, Kawakami S, Fukuda J, Haga Y, Kukidome D, Takahashi T, Araki E.

J Diabetes Investig. 2018 Nov;9(6):1370-1377. doi: 10.1111/jdi.12848. Epub 2018 Apr 29.

33.

Effects of a novel selective peroxisome proliferator-activated receptor-α modulator, pemafibrate, on hepatic and peripheral glucose uptake in patients with hypertriglyceridemia and insulin resistance.

Matsuba I, Matsuba R, Ishibashi S, Yamashita S, Arai H, Yokote K, Suganami H, Araki E.

J Diabetes Investig. 2018 Nov;9(6):1323-1332. doi: 10.1111/jdi.12845. Epub 2018 Apr 26.

34.

Japanese Clinical Practice Guideline for Diabetes 2016.

Haneda M, Noda M, Origasa H, Noto H, Yabe D, Fujita Y, Goto A, Kondo T, Araki E.

J Diabetes Investig. 2018 Mar 26. doi: 10.1111/jdi.12810. [Epub ahead of print] No abstract available. Erratum in: J Diabetes Investig. 2019 Jan;10(1):190.

35.

Shallow very-low-frequency earthquakes accompany slow slip events in the Nankai subduction zone.

Nakano M, Hori T, Araki E, Kodaira S, Ide S.

Nat Commun. 2018 Mar 14;9(1):984. doi: 10.1038/s41467-018-03431-5.

36.

Inhibition of Local Macrophage Growth Ameliorates Focal Inflammation and Suppresses Atherosclerosis.

Yamada S, Senokuchi T, Matsumura T, Morita Y, Ishii N, Fukuda K, Murakami-Nishida S, Nishida S, Kawasaki S, Motoshima H, Furukawa N, Komohara Y, Fujiwara Y, Koga T, Yamagata K, Takeya M, Araki E.

Arterioscler Thromb Vasc Biol. 2018 May;38(5):994-1006. doi: 10.1161/ATVBAHA.117.310320. Epub 2018 Mar 1.

PMID:
29496659
38.

The clinical course and pathophysiological investigation of adolescent gestational diabetes insipidus: a case report.

Kondo T, Nakamura M, Kitano S, Kawashima J, Matsumura T, Ohba T, Yamaguchi M, Katabuchi H, Araki E.

BMC Endocr Disord. 2018 Jan 30;18(1):4. doi: 10.1186/s12902-018-0234-6.

39.

Identification of microRNA that represses IRS-1 expression in liver.

Ono K, Igata M, Kondo T, Kitano S, Takaki Y, Hanatani S, Sakaguchi M, Goto R, Senokuchi T, Kawashima J, Furukawa N, Motoshima H, Araki E.

PLoS One. 2018 Jan 24;13(1):e0191553. doi: 10.1371/journal.pone.0191553. eCollection 2018.

40.

Effects of Pemafibrate, a Novel Selective PPARα Modulator, on Lipid and Glucose Metabolism in Patients With Type 2 Diabetes and Hypertriglyceridemia: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial.

Araki E, Yamashita S, Arai H, Yokote K, Satoh J, Inoguchi T, Nakamura J, Maegawa H, Yoshioka N, Tanizawa Y, Watada H, Suganami H, Ishibashi S.

Diabetes Care. 2018 Mar;41(3):538-546. doi: 10.2337/dc17-1589. Epub 2018 Jan 3.

PMID:
29298800
41.

[Anterior Mediastinal Myxoid Liposarcoma Detected by Chest Computed Tomogram in the Patient with Pneumothorax].

Nakashima S, Maeda T, Muraki S, Sakurada T, Sasaki J, Araki E, Osawa H, Watanabe A.

Kyobu Geka. 2017 Dec;70(13):1083-1086. Japanese.

PMID:
29249787
42.

Sporadic low-velocity volumes spatially correlate with shallow very low frequency earthquake clusters.

Tonegawa T, Araki E, Kimura T, Nakamura T, Nakano M, Suzuki K.

Nat Commun. 2017 Dec 11;8(1):2048. doi: 10.1038/s41467-017-02276-8.

43.

Efficacy and safety of pemafibrate (K-877), a selective peroxisome proliferator-activated receptor α modulator, in patients with dyslipidemia: Results from a 24-week, randomized, double blind, active-controlled, phase 3 trial.

Ishibashi S, Arai H, Yokote K, Araki E, Suganami H, Yamashita S; K-877 Study Group.

J Clin Lipidol. 2018 Jan - Feb;12(1):173-184. doi: 10.1016/j.jacl.2017.10.006. Epub 2017 Oct 28.

44.

Recurring and triggered slow-slip events near the trench at the Nankai Trough subduction megathrust.

Araki E, Saffer DM, Kopf AJ, Wallace LM, Kimura T, Machida Y, Ide S, Davis E; IODP Expedition 365 shipboard scientists.

Science. 2017 Jun 16;356(6343):1157-1160. doi: 10.1126/science.aan3120.

PMID:
28619941
45.

Impaired balance is related to the progression of diabetic complications in both young and older adults.

Kukidome D, Nishikawa T, Sato M, Nishi Y, Shimamura R, Kawashima J, Shimoda S, Mizuta H, Araki E.

J Diabetes Complications. 2017 Aug;31(8):1275-1282. doi: 10.1016/j.jdiacomp.2017.05.014. Epub 2017 Jun 4.

PMID:
28610947
46.

Efficacy and safety of K-877, a novel selective peroxisome proliferator-activated receptor α modulator (SPPARMα), in combination with statin treatment: Two randomised, double-blind, placebo-controlled clinical trials in patients with dyslipidaemia.

Arai H, Yamashita S, Yokote K, Araki E, Suganami H, Ishibashi S; K-877 Study Group.

Atherosclerosis. 2017 Jun;261:144-152. doi: 10.1016/j.atherosclerosis.2017.03.032. Epub 2017 Mar 24.

47.

Low glucose induces mitochondrial reactive oxygen species via fatty acid oxidation in bovine aortic endothelial cells.

Kajihara N, Kukidome D, Sada K, Motoshima H, Furukawa N, Matsumura T, Nishikawa T, Araki E.

J Diabetes Investig. 2017 Nov;8(6):750-761. doi: 10.1111/jdi.12678. Epub 2017 May 24.

48.

Causes of death in Japanese patients with diabetes based on the results of a survey of 45,708 cases during 2001-2010: Report of the Committee on Causes of Death in Diabetes Mellitus.

Nakamura J, Kamiya H, Haneda M, Inagaki N, Tanizawa Y, Araki E, Ueki K, Nakayama T.

J Diabetes Investig. 2017 May;8(3):397-410. doi: 10.1111/jdi.12645. Epub 2017 Mar 27.

49.

Causes of death in Japanese patients with diabetes based on the results of a survey of 45,708 cases during 2001-2010: report of Committee on Causes of Death in Diabetes Mellitus.

Nakamura J, Kamiya H, Haneda M, Inagaki N, Tanizawa Y, Araki E, Ueki K, Nakayama T.

Diabetol Int. 2017 Mar 28;8(2):117-136. doi: 10.1007/s13340-017-0313-3. eCollection 2017 Jun.

50.

Efficacy and safety of dapagliflozin over 1 year as add-on to insulin therapy in Japanese patients with type 2 diabetes: the DAISY (Dapagliflozin Added to patients under InSulin therapY) trial.

Araki E, Onishi Y, Asano M, Kim H, Yajima T.

Diabetes Obes Metab. 2017 Apr;19(4):562-570. doi: 10.1111/dom.12853. Epub 2017 Feb 23.

PMID:
27987240

Supplemental Content

Support Center